{
    "Trade/Device Name(s)": [
        "N Antisera to Human Ceruloplasmin",
        "N Antisera to Human Ceruloplasmin Assay"
    ],
    "Submitter Information": "Dade Behring Marburg GmbH",
    "510(k) Number": "K053074",
    "Predicate Device Reference 510(k) Number(s)": [
        "K860894"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DDB"
    ],
    "Summary Letter Date": "March 16, 2006",
    "Summary Letter Received Date": "November 1, 2005",
    "Submission Date": "October 28, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.5210"
    ],
    "Regulation Name(s)": [
        "Ceruloplasmin immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Ceruloplasmin",
        "Hemopexin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Heparinized plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BN\u2122 Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Immunonephelometry"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for N Antisera to Human Ceruloplasmin for quantitative determination of ceruloplasmin and hemopexin in serum and heparinized plasma using immunonephelometry",
    "Indications for Use Summary": "In vitro diagnostic reagents for quantitative determination of ceruloplasmin and hemopexin in serum and heparinized plasma by immunonephelometry on BN\u2122 Systems; measurement of ceruloplasmin aids in diagnosis of copper metabolism disorders",
    "fda_folder": "Immunology"
}